GlassScriptPhysician profile
Uday N Bhatt
NPI 1033147483
$8,002.35
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $955 · 2020: $1,187 · 2021: $2,935 · 2022: $1,781 · 2023: $1,104 · 2024: $40.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,144.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $3,392.82 | 2019-2023 | Senza |
| Abbott Laboratories | $1,454.05 | 2019-2023 | Proclaim, Octrode |
| Medtronic, INC. | $685.79 | 2021-2022 | |
| Boston Scientific Corporation | $419.19 | 2019-2021 | |
| Si-Bone, INC. | $372.91 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $307.19 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $304.47 | 2019-2024 | Xtampza, Belbuca |
| Stryker Corporation | $256.49 | 2019-2022 | |
| Novo Nordisk INC | $120.16 | 2020 | |
| Horizon Therapeutics Plc | $115.07 | 2020-2022 | |
| Depuy Synthes Sales INC. | $95.96 | 2020-2023 | Orthovisc, Peak, Monovisc |
| Vertos Medical, INC. | $86.06 | 2019 | |
| Azurity Pharmaceuticals, INC. | $75.23 | 2023-2024 | Horizant, Horizant |
| Astrazeneca Pharmaceuticals LP | $61.38 | 2019 | |
| Grt US Holding, INC. | $52.62 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $40.29 | 2019 | |
| Biodelivery Sciences International, INC. | $29.50 | 2021 | |
| Redhill Biopharma INC. | $28.61 | 2020-2021 | |
| Stratus Medical, LLC | $15.99 | 2023 | Nimbus |
| Arbor Pharmaceuticals, INC. | $14.50 | 2021 | |
| Pfizer INC. | $14.38 | 2019 | |
| Hikma Pharmaceuticals USA | $12.46 | 2021 | |
| Iroko Pharmaceuticals, LLC | $12.45 | 2019 | |
| Pacira Therapeutics, INC. | $12.06 | 2019 | |
| Fidia Pharma USA INC. | $11.47 | 2019 | |
| Mdd US Operations, LLC | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uday Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.